- Company/Commercial (48)
- Corporate (37)
- Banking / Finance (22)
- Regulatory and compliance (15)
- Financial services (14)
- Information Technology (14)
- Employment (11)
- Funds (11)
- Insurance/reinsurance (7)
- Energy (6)
- Environment (6)
- Tax (6)
- Crime (4)
- Healthcare (4)
- Media/Entertainment/Sport (3)
- Insolvency & restructuring (2)
- Intellectual Property (2)
- Litigation / Dispute Resolution (2)
- Pharma/Biotech (2)
- Real Estate (2)
- Telecoms (2)
- Charities (1)
- Construction (1)
- Family (1)
- Immigration (1)
- In-House (1)
- Other (1)
- Planning (1)
- Public Sector/Local Authority (1)
- Suppliers (1)
69 articles matched your search
Sort By: Newest first | Oldest first
KPMG has revealed that 58 per cent of family businesses are currently seeking external financing to fund their plans, but finding the right strategic partner can be challenging.
The role of business is increasingly being scrutinised, debated and challenged. As a business community, we need to be aware of this trend and respond to it.
KPMG has called for the EU’s financial services regulatory reform agenda to be re-evaluated to avoid a serious risk to businesses, jobs and economic growth.
The Nigerian banking landscape continues to face significant headwinds on its bottom line — both from the top line and costs.
KPMG’s M&A Predictor is a forward-looking tool that helps member firm clients to forecast worldwide trends in mergers and acquisitions.
Oman’s newly signed treaty with Spain reduces withholding tax rates and includes a new limitation on benefits clause to prevent treaty shopping.
With so many Nigerians happily surfing the net, why have local banks not converted more of these sophisticated web users into internet banking customers?
KPMG has commented following the IASB’s issuance of the fourth and final version of its new standard on financial instruments accounting — IFRS 9 Financial Instruments.
In this year’s Top of Mind Survey, 469 consumer executives were asked how technology and other consumer and industry trends were influencing their corporate strategies.
As spending on pharmaceutical R&D continues to soar, executives, shareholders and analysts alike are entitled to ask: what value are we getting for our investment?